Evie Ring (and EvieMED) at United States

Movano Health (NASDAQ: MOVE; led by chief executive John Mastrototaro) makes the women's-health-focused Evie smart ring, recorded in the biometric form factor, with cycle tracking and women's-health metrics as its editorial differentiator. A load-bearing entity split applies: there are two rings, the consumer Evie Ring, which tracks the menstrual cycle, sleep, energy, heart rate, blood oxygen, and mood as a general-wellness device that is not FDA-cleared, and the separate business-to-business EvieMED Ring, which received an FDA 510(k) clearance for its pulse oximeter and heart rate on December 2, 2024 for clinical trials, remote patient monitoring, and payor and pharma use, with a pivotal study showing accuracy across darker skin tones, so the clearance must not be attributed to the consumer Evie Ring.

A significant financial cap-flag is the real risk here: Movano is distressed, with its SEC filings showing going-concern substantial doubt, an accumulated deficit of $160.5 million as of September 30, 2025, cash not sufficient to fund operations beyond the first quarter of 2026 without further capital or a merger, a strategic review and possible sale underway, a one-for-ten reverse stock split in October 2025 to regain NASDAQ compliance, and a $1.5 million bridge loan at an effective rate around 111.6 percent secured by the company's intellectual property that transfers to the lender if a merger fails to close, so the registry records it at commercial maturity but at risk with an active lifecycle and a re-verification flag given the volatile status. A source-drift note: a secondary article cites a stale 2024 cash figure that the SEC filings supersede with the going-concern position, and the company's market-size framing is total-addressable-market language rather than verified revenue.